Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Technology Scientific & Technical Instruments
Arch Biopartners Inc. is a portfolio-based biotechnology company focused on the development of technologies that have the potential to make a medical or commercial impact. The Company is focused on the clinical development of its drug platform in targeting dipeptidase-1 (DPEP-1) mediated organ inflammation in the lungs, liver and kidneys. Its lead drug candidate is LSALT Peptide (Metablok... see more

Recent & Breaking News (TSXV:ARCH)

Arch Biopartners Enters Exclusive License Agreement with the University of Cincinnati for AB569 Topical Wound Treatment

GlobeNewswire March 24, 2021

Arch Biopartners (TSXV:ARCH) receives authorization to amend Phase II drug trial protocol

Simon Druker  March 16, 2021

Arch Biopartners Receives Health Canada Authorization to Amend Phase II Trial Protocol for LSALT Peptide

GlobeNewswire March 16, 2021

ARCH Scientist Publishes Paper Showing Pre-Clinical Efficacy of AB569 in Eradicating Multi-Drug Resistant Pathogens Acinetobacter baumannii and Acinetobacter spp

GlobeNewswire March 4, 2021

Peter Lougheed Centre Joins the Phase II Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients

GlobeNewswire February 26, 2021

Arch Biopartners Receives Ethics Committee Approval in Turkey to Dose Additional Patients in the Phase II Trial for LSALT Peptide

GlobeNewswire February 2, 2021

University of Calgary Joins the Phase II Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients

GlobeNewswire January 5, 2021

Arch Biopartners Closes Non-Brokered Private Placement

GlobeNewswire December 29, 2020

Arch Biopartners Arranges Non-Brokered Private Placement

GlobeNewswire December 23, 2020

InvestmentPitch Media Video Discusses Arch Biopartners' Awarding of $6.7 Million from Canadian Government's Strategic Innovation Fund - Video Available on Investmentpitch.com

Newsfile December 17, 2020

IIROC Trading Resumption - ARCH

Canada NewsWire December 15, 2020

Arch Biopartners Receives Government of Canada Funding to Support Phase II Therapeutic Trial of Metablok for COVID-19

GlobeNewswire December 15, 2020

IIROC Trading Halt - ARCH

Canada NewsWire December 15, 2020

VA San Diego Healthcare System Joins the Phase II Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients

GlobeNewswire December 10, 2020

Arch Biopartners Announces Dosing of First Patient in Turkey in Phase II Trial of LSALT peptide to Treat Complications from Covid-19

GlobeNewswire November 5, 2020

First Patient Dosed in Phase II Trial to Treat Complications in COVID-19

GlobeNewswire October 16, 2020

Arch Biopartners Receives Approval from Turkish Ministry of Health to Proceed with Phase II Trial for LSALT Peptide; Begins Screening Patients in Florida

GlobeNewswire October 7, 2020

Arch Biopartners Receives Ethics Committee Approval in Turkey for Phase II Trial for LSALT Peptide

GlobeNewswire September 10, 2020

Arch Biopartners Announces Application to the Turkish Ministry of Health to Conduct Phase II Trial for Treatment of Complications in COVID-19 patients

GlobeNewswire September 1, 2020

Arch Biopartners Obtains DTC Eligibility for its Common Shares on OTCQB

GlobeNewswire August 21, 2020